21
George Perry Semmes Foundation Distinguished University Chair in Neurobiology The University of Texas at San Antonio RegenMed SA Session III – Clinical Progress & Applicaitons Alzheimer ‘Disease-in-a- Dish’ and Development of Novel Therapeutics San Antonio, Texas 12 February 2016 1

Alzheimer 'Disease-in-a-Dish' and Development of Novel Therapeutics

Embed Size (px)

Citation preview

Page 1: Alzheimer 'Disease-in-a-Dish' and Development of Novel Therapeutics

1

George PerrySemmes Foundation Distinguished University Chair in Neurobiology

The University of Texas at San Antonio

RegenMed SASession III – Clinical Progress & Applicaitons

Alzheimer ‘Disease-in-a-Dish’ and Development of Novel Therapeutics

San Antonio, Texas 12 February 2016

Page 2: Alzheimer 'Disease-in-a-Dish' and Development of Novel Therapeutics

2

Page 3: Alzheimer 'Disease-in-a-Dish' and Development of Novel Therapeutics

3

Alzheimer disease is a complex biological and social condition that requires development of new technical and conceptual insights to be solved.

While we can see the disease in humans, it is difficult to dissect and while we can study the components in animals and their cells, it only models portions of the disease.

Page 4: Alzheimer 'Disease-in-a-Dish' and Development of Novel Therapeutics

4

Poor models are the major reason 99.6% of AD drugs have failed. Our goal is to develop a stem cell model of human AD as a platform to understand human AD and drug development.

Alzheimer disease patients live for years with every feature of normal physiology, cell biology, molecular, and social interaction altered.

Traditionally we have used:1) Human tissue and proteins2) Animal models, either normal or genetically modified3) Cell culture models

a. Animalb. Humanc. Stem cell technology

Page 5: Alzheimer 'Disease-in-a-Dish' and Development of Novel Therapeutics

5

CaMKII promotor tTA

tetO MYCp

Dox

Activation Inactivation

Establishment of an animal model CaMKII-MYC mice

MYC is specifically induced in cerebral cortical and hippocampal neurons by depletion of doxycyline

C-MYC (now referred to as MYC) is a member of a family of proto-oncogenes comprising C-MYC, N-MYC, and L-MYC. MYC encodes a transcription factor that, as part of a heterodimeric complex with MAX, regulates the expression of a multitude of genes involved in regulating cellular proliferation and growth. Overexpression of MYC is commonly associated with tumorigenesis. Where MYC exerts its neoplastic function by inducing autonomous cellular proliferation and cellular growth, blocking differentiation, and inducing genomic destabilization.

Cere

bral

Cor

tex

Brai

n st

emCe

rebe

llum

Page 6: Alzheimer 'Disease-in-a-Dish' and Development of Novel Therapeutics

6

Selective Neurodegeneration in CaMKII-MYC mice

MYC-ON MYC-OFF

Page 7: Alzheimer 'Disease-in-a-Dish' and Development of Novel Therapeutics

7

Oxidative stress is an early event in AD.

......

t

GlycationNormalNeuron

? Pre-NFT I-NFT E-NFT

FREE CARBONYLS

80HGHNE

Potential Mechanisms of Reactive Oxygen Species

Generation in apparently normal neurons in Alzheimer Disease

Active microglia

Redox active metals

Amyloid-b

Advanced glycation endproducts

Mitochondria??

Human Tissue

Page 8: Alzheimer 'Disease-in-a-Dish' and Development of Novel Therapeutics

8

Page 9: Alzheimer 'Disease-in-a-Dish' and Development of Novel Therapeutics

9

Alzheimer Control

In situ hybridization of mtDNA

Immunolocalization of Cytochrome oxidase 1 is increased in AD

Alzheimer disease Control

Mitochondrial components are increased in Alzheimer disease

Wi l d type probe

Chi mera probe

4977 bp del et i on

Deleted mtDNANormal mtDNA

8482 108978454 10941

1347513475

8454

8482/ 1346013460

ACACAAACTACCACCTACCTCCCTCACCATTGGCAGCCTA GCATT

CAACAACCTATTTAGCTGTTCCCCAACCTTTTCCTCCGACCCCCT

16, 569 bp 11, 592 bpOHOH

4977 bp del et i on cont ai ns ATPase subuni t 8, subuni t 6, cyt ochrome-c oxi dase subuni t I I I , and NADH-coenzyme Q oxi dor educt ase subuni t 3, 4 and 5.

Page 10: Alzheimer 'Disease-in-a-Dish' and Development of Novel Therapeutics

10

Examination of neurons in biopsy specimens shows normal mitochondria (A), mitochondria with broken cristae (B), and lipofuscin with vacuoles (C).

0

0 . 2

0 . 4

0 . 6

0 . 8

1

Numb

er p

er

m

2

A DC o n t r o l

0

0 . 2

0 . 4

0 . 6

0 . 8

1

Size in

m2

0

2

4

6

8

1 0

Perce

ntag

e o

f are

a

To

ta

l

mi

to

ch

on

dr

ia

No

rm

al

mi

to

ch

on

dr

ia

Br

ok

en

cr

ist

ae

mi

to

ch

on

dr

ia

Va

cu

ola

r

lip

of

us

ci

n

Ele

ctr

on

de

ns

e

lip

of

us

cin

H i r a i e t a l .

F i g u r e 7

*

Mitochondria0

0 . 2

0 . 4

0 . 6

0 . 8

1

Num

ber pe

r

m2

A DC o n t r o l

0

0 . 2

0 . 4

0 . 6

0 . 8

1

Size in

m

2

0

2

4

6

8

1 0

Perc

entag

e of a

rea

To

tal

mit

oc

ho

nd

ri

a

No

rm

al

mit

oc

ho

nd

ri

a

Br

ok

en

cr

ist

ae

mit

oc

ho

nd

ri

a

Va

cu

ola

r

lip

of

us

cin

Ele

ctr

on

de

ns

e

lip

of

us

cin

H i r a i e t a l .

F i g u r e 7

Percentage area of intact mitochondria is significantly decreased in cases of AD (n=8) as compared to age-matched controls (n=5). p=0.012

While mtDNA is increased, mitochondria are not.

Page 11: Alzheimer 'Disease-in-a-Dish' and Development of Novel Therapeutics

DDisbursed mt

Collapsed mtN

umbe

r of M

itoch

ondr

ia

ADNormalM

ean

of M

itoch

ondr

ia

Leng

th (m

icro

met

ers)

ADNormal

AD Fibroblasts

ADNormal

% o

f col

laps

ed

mito

chon

dria

11

Page 12: Alzheimer 'Disease-in-a-Dish' and Development of Novel Therapeutics

Fission Fusion

A Delicate Balance between Mitochondrial Fission and Fusion

12

Page 13: Alzheimer 'Disease-in-a-Dish' and Development of Novel Therapeutics

13

Normal AD

Normal

Normal

AD AD

Decreased DLP1 levels are found in AD fibroblasts

Page 14: Alzheimer 'Disease-in-a-Dish' and Development of Novel Therapeutics

14

Reduction of DLP1 levels in normal cell fibroblasts by iRNA affects mitochondria

Page 15: Alzheimer 'Disease-in-a-Dish' and Development of Novel Therapeutics

15

Mitochondrial morphology and distribution in rat E18 primary neurons (DIV 7) either overexpressing or knocking down mitochondrial

fission/fusion proteins

Page 16: Alzheimer 'Disease-in-a-Dish' and Development of Novel Therapeutics

16

Tubulin DsRed-Mono Mito-AcGFP DAPi Merged

DsRed-Mono vector

WT AβPP- DsRed-Mono

AβPPswe-DsRed-Mono

AβPPswe-DsRed-Mono+ BACE inhibitor IV

A

Vector Vector+inhibitor WT APP WT APP+inhibitor APPswe APPswe+inhibitor0

102030405060708090

100

Normal Fragmented Elongated

% o

f co-

tran

sfec

ted

Cells

wit

h va

riou

s mi-

toch

ondr

ial m

orph

olog

y

* *

*

*

*

*

**

*

Vector Vector+inhibitor WT APP WT APP+inhibitor APPswe APPswe+inhibitor0

10

20

30

40

50

60

70%

of C

ells

with

abn

orm

al m

i-to

chon

dria

l dis

trib

utio

n

*

*

*

B

C D

0

20

40

60

80

100R² = 0.938039966911449

0

20

40

60

80

100R² = 0.958907420307873

0 1000 2000 3000 4000 5000 60000

20

40

60

80

100

R² = 0.946331381866869

Ab

% c

ells

with

abn

orm

al

mito

chon

dria

l dis

tribu

tion

% c

ells

with

frag

men

ted

mito

chon

dria

% c

ells

with

nor

mal

m

itoch

ondr

ia

Aβ Overproduction Underlies AβPP-Induced Mitochondrial Abnormalities

Page 17: Alzheimer 'Disease-in-a-Dish' and Development of Novel Therapeutics

17

Amyloid plaque cores purified from brain demonstrate characteristic Congo red birefringence (A), are strongly reactive with antisera to Ab 1-42 (B), but not with irrelevant antisera (C).

A

B

C

Spectra of plaque cores (B) are virtually identical to synthetic peptide (A). Intensity at 1604 is indicative of Zn binding and at 1278 for Cu binding, both increased in purified cores.

B sheet

Zn bindingCu binding

Page 18: Alzheimer 'Disease-in-a-Dish' and Development of Novel Therapeutics

18

Page 19: Alzheimer 'Disease-in-a-Dish' and Development of Novel Therapeutics

19

Imaging Mass Spectrometry

Page 20: Alzheimer 'Disease-in-a-Dish' and Development of Novel Therapeutics

20

Alzheimer’s Patient (APOE3/4)

Green = bIII tubulinBlue = DNA

Green = MAP2Blue = DNA

Control Patient

Human Neuronal Cells Derived from Fibroblasts

Page 21: Alzheimer 'Disease-in-a-Dish' and Development of Novel Therapeutics

21

Conclusion

Development of human-based AD cell models will allow us to understand the uniquely human disease with greater clarity than prior approaches, where parallels were compared with rodents.